IMI Graham Hughes
-
Upload
ck-group -
Category
Technology
-
view
741 -
download
1
description
Transcript of IMI Graham Hughes
![Page 1: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/1.jpg)
1
Innovative Medicines Initiative
Graham HughesUK National Contact Point Health
"By joining the best academic teams with high-level industry scientists, IMI is building the research capacity needed to cure the major diseases of our time." Michel Goldman, IMI Executive Director
![Page 2: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/2.jpg)
2
Innovative Medicines Initiative
![Page 3: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/3.jpg)
3
IMI in the Health Theme
Activity 1:Biotechnology, generic tools & technologies for health
Activity 2:Translating research for
human health
Activity 3:Optimising the delivery of health care
cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issues
Activity 4: Support actions & response to policy needs
The Innovative Medicines Initiative
![Page 4: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/4.jpg)
4
Why is IMI needed?
![Page 5: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/5.jpg)
5
What are the Expected Results?
• To modernise the development process of medicines; • To drive the development of innovative medicines with a
high level of safety and efficacy, for millions of patients; • To generate more and better quality jobs for scientists,
reversing the European brain drain; • To enhance European expertise and know-how in new
technologies to attract pharmaceutical R&D investment to Europe;
• To create a stronger competitive advantage for smaller companies (SMEs, spin-offs and start-ups) and public organisations by collaborating with a multitude of stakeholders.
![Page 6: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/6.jpg)
6
How to Achieve Results
• Support “pre-competitive pharmaceutical research and development” – accelerate the development of safer and more effective medicines for patients
• Modernization of the drug development process, via new approaches, methods and technologies, better use of research results and data and more skilled staff
• Foster collaboration between stakeholders , e.g industry, academia, patient organisations, public authorities (inc regulators) , clinical centres etc
• Addresses the challenges in the development process of drugs rather than aiming to deliver new medicines
![Page 7: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/7.jpg)
7
How is it funded?
EFPIA members fully fund their own participation and provide R&D resources such as staff, laboratories, materials and clinical research.
EU funds exclusively public organisations or nonprofit organisations and small and medium-sized enterprises (SMEs).
![Page 8: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/8.jpg)
8
IMI Governance
Founding Members Overall Responsibility for operations of
IMI
Responsible for day to day management
15 Members Provide scientific advice to the board
Governing Board
Executive Director ( + staff)
Scientific CommitteeIMI J
oint
Und
erta
king
Stakeholder Forum
Annual meeting open to all stakeholders
Communication and Feedback
IMI States Representatives Group
One representative per MS or AS
Chair is observer on Governing Board
![Page 9: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/9.jpg)
9
IMI Research Agenda
![Page 10: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/10.jpg)
10
IMI Projects: Key facts
• Open and competitive calls with a peer review process by independent experts
• Average project size €15 - 20 million• Average consortium size in the range of:
- 9 – 16 pharmaceutical companies- 9 – 37 academic, SME, regulatory, patient organisations
• EU funding to academic, SME and other partners is– 75% of total eligible research costs– 100% of total eligible management and training costs
• Total eligible costs include direct eligible costs plus 20% overheads
![Page 11: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/11.jpg)
11
IMI Research Consortium
![Page 12: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/12.jpg)
12
IMI Call Process
Timeline
Grant and Project AgreementsFull Project Consortium
Involvement
EFPIA Consortium
Applicant Consortium
Applicant and EFPIA Consortium
Full Project Consortium
Full Project Proposal
2nd Peer Review
Evaluation Stage 2
Phase Activity
Expressions of Interest
1st Peer Review
Invitation to join for full Project Proposal
Evaluation Stage 1
Research Agenda
Annual Implementation Plan
Call with topics
Call Definition17 Nov 09
08 Feb 10
March 10
Q4 2010
![Page 13: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/13.jpg)
13
1st Call (2008)
15 Projects
395 teams24 SMEs11 patient organisations
EU Budget = €281 Million
Pillars:• Drug Safety• Education and Training
Thematic Areas• Neurosciences• Diabetes• Lung Disease
UK SMEsCXR BiosciencesPsynova NeurotechSynairgen ReasearchChoice Pharma
![Page 14: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/14.jpg)
14
2nd Call (2009)
Projects start March 2011
8 Projects
65EFPIA teams103 Academic teams23 SMEs2 patient organisations
EU Budget = €172 Million
Pillars:• Drug Efficacy• Knowledge Management
Thematic Areas• Cancer• Rheumatoid Arthritis• Infectious Disease
UK SMEsCyprotex DiscoveryMango Business SolutionsSimcyp LtdAssero LtdAcademic Concept Knowledge Ltd
![Page 15: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/15.jpg)
15
3rd Call (2010)
Launched 22 Oct 2010EoI Deadline 18 Jan 2011Evaluations March/April
EU Budget = €114 Million
Pillars:• Drug Safety• Drug efficacy
• Education and Training
Thematic Areas• Inflammatory Disease• Neurological Disease
• Infectious Disease• Diabetes
![Page 16: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/16.jpg)
16
4th Call
![Page 17: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/17.jpg)
Technology Strategy BoardDriving Innovation
Launch Date 17th June 2011
![Page 18: IMI Graham Hughes](https://reader034.fdocuments.us/reader034/viewer/2022051412/5497a00eb47959744d8b52ee/html5/thumbnails/18.jpg)
18
Support
http://www.imi.europa.eu